GPX4 and stroke disorder: Compared with the MCAO group, MCAO with liproxstatin-1 treatment significantly attenuated the decrease in the protein level of GPx4 in mice caused by stroke (MCAO vs MCAO + Lip group: 0.32 ± 0.06 vs 0.48 ± 0.11, p ≤ 0.05; n = 5, one-way ANOVA, Figures 2A,B).